

10/519323

DT'c'd PCT/PTO 2 3 DEC 2004

PATENT
4518-0107PUS1

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: LOIBNER, Hans et al.
Appl. No.: NEW Group:
Filed: December 23, 2004 Examiner:
For: USE OF A PREPARATION BASED ON AN
ANTIBODY DIRECTED AGAINST A TUMOR-
ASSOCIATED GLYCOSYLATION

INFORMATION DISCLOSURE STATEMENT
(SUBMISSION CONCURRENT WITH THE
FILING OF A NEW PATENT APPLICATION)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

December 23, 2004

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on PTO-1449, attached hereto.

II. COPIES

- a. ☒ Copies of cited U.S. patents and patent application publications are not included. Copies of foreign patent documents and non-patent literature are included.
- b. ☒ This application is a National Phase of a PCT application. Some or all of the documents listed on the PTO-1449 are not enclosed because they were cited in the International Search Report and copies should be forwarded from the International Search Authority. If copies are needed, please contact the undersigned.

III. CONCISE EXPLANATION OF THE RELEVANCE
(check at least one box)

a. ☐ DOCUMENTS IN THE ENGLISH LANGUAGE

The patents, publications, or other information listed on the attached PTO 1449 are in the English language and therefore, do not require a statement of relevancy.

b. ☒ DOCUMENTS NOT IN THE ENGLISH LANGUAGE

A concise explanation of the relevance of all patents, publications, or other information listed that is not in the English language is as follows:

WO 02/33073 A1 - English language abstract attached

c. ☐ ENGLISH LANGUAGE SEARCH REPORT

An English language version of the search report or action that indicates the degree of relevance found by the foreign office is attached, thereby satisfying the requirement for a concise explanation. See MPEP 609(III)(A)(3).

d. ☐ OTHER

The following additional information is provided for the Examiner's consideration.

10/519323
DT09 PCT/PTO 2 3 DEC 2004

Docket No. 4518-0107PUS1

FEES


This Information Disclosure Statement is being filed concurrently with the filing of a new patent application; therefore, no fee is required.

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule and charge the appropriate fee to Deposit Account No. 02-2448.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By 

Leonard R. Svensson, #30,330

LRS/lmt
4518-0107PUS1

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

Attachment(s): ☒ Form PTO-1449(s)
☒ Documents
☐ Foreign Search Report
☐ Fee
☐ Other: _____

Form PTO-1449

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

ATTY. DOCKET NO.

4518-0107PUS1

APPLICATION NO.

10/519323

APPLICANT

LOIBNER, Hans et al.

FILING DATE

December 23, 2004

GROUP

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	Kind	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	US						
	US						
	US						
	US						
	US						
	US						
	US						
	US						
	US						
	US						

FOREIGN PATENT DOCUMENTS

	Office	DOCUMENT NUMBER	Kind	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
								YES	NO
	EP	0528767	A	1993-02-24	EUROPE				
	WO	0100245	A	2001-01-04	WO				
	WO	02092771	A	2002-11-21	WO				
	WO	0170268	A1	2001-09-21	WO ✓				
	WO	8911288	A1	1989-11-30	WO ✓				
	WO	0233073	A1	2002-04-25	WO ✓				X

OTHER DOCUMENTS

(Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.

	DETTKE, M. et al.: "Different types of FCgamma-receptors are involved in anti-Lewis Y antibody induced effector functions in vitro" British Journal of Cancer, Vol. 82, No. 2, January 2000, pp. 441-445
	BASU, A. et al. "Presence of tumor-associated antigens in epidermal growth factor receptors from different human carcinomas" Cancer Research, Vol. 47, No. 10, 15 May 1987, pp. 2531-2536
	GOOI, H.C. et al: "Monoclonal antibody (EGR/G49) reactive with the epidermal growth factor receptor of A431 cells recognizes the blood group ALeb and ALey structures" Molecular Immunology, Vol. 22, No. 6, June 1985, pp. 689-693
	BRICH, Z. et al: "Preparation and characterization of a water soluble dextran immunoconjugate of doxorubicin and the monoclonal antibody (ABL 364)" Journal of Controlled Release, Vol. 19, No. 1/3, 1 March 1992, pp. 245-257

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.